Changing the Treatment Paradigm in Cancer and Fibrotic Disease

learn more >


BLR Bio has a library of “first in class” biomolecules working through a novel approach to regulate key CCN signaling pathways.

The therapeutic approach includes targeting the control of the cancer stroma/ECM microenvironment, as well as direct cell replication, creating an environment for re-establishment of complete tissue homeostasis.

In parallel, a diagnostic / theranostic platform has been created and is being advanced. It was designed to provide earlier and more accurate diagnosis, better patient selection, and an early readout of efficacy allowing patient customized therapy. It can be both paired with our therapy as well as those of others.

Additional information is available by contacting us.

Some programs are still confidential. As they such may not be disclosed on this list. Also, the list of potential indications for candidates go beyond those described here. Please contact us if you are interested in other indications.

(Click to enlarge)

© BLR Bio, L.L.C. | 313 54th Street, Kenosha, WI, USA, 53140 |

Latest News

May 2016
"Dr. Bruce Riser, CEO of BLR Bio, was an invited speaker on Peptide Discovery, Preclinical and Clinical presented at the TIDES Oligonucleotide and Peptide Therapeutics Conference, at Long Beach. See selected pre-interview."

April 2016
"BLR Bio was selected as one of the top 50 emerging biotechnology companies to present at the MedCity INVEST, Health Tech Showcase in Chicago April 10-12."

see news archives »


April 2016
Balanced Regulation of the CCN Family of Matricellular Proteins: A Novel Approach to the Prevention and Treatment of Fibrosis and Cancer.
Journal of Cell Communication and Signaling 9.4 (2015): 327–339.
PMC. Web. 28 Apr. 2016.

more publications »